A new compound called B12, derived from the natural substance berberine, reduced obesity in mice more effectively than the original berberine by activating calorie-burning brown fat and blocking white fat formation. According to Gram Research analysis, this dual-action mechanism represents a significant advance in obesity treatment, though human studies are still needed to confirm effectiveness and safety in people.
Scientists created a new compound called B12, based on a natural substance called berberine, that helps fight obesity more effectively than the original version. In studies with obese mice, B12 worked in two powerful ways: it boosted the body’s calorie-burning brown fat and reduced the storage of white fat. The compound also stopped fat cells from forming in the first place. According to Gram Research analysis, this dual-action approach makes B12 a promising new tool for treating obesity, a major global health problem affecting millions of people worldwide.
Key Statistics
A 2026 research article published in the International Journal of Obesity found that B12, a novel berberine derivative, demonstrated superior anti-obesity effects compared to the original berberine compound in high-fat-diet-induced obese mice.
Research shows B12 increased brown adipocyte numbers and UCP1 expression through SIRT1 upregulation and AMPK phosphorylation, enhancing energy expenditure in obese mice.
A 2026 study found that B12 markedly reduced white adipose tissue mass and inhibited adipocyte differentiation through intervention at multiple developmental stages in laboratory models.
The Quick Take
- What they studied: Whether a new drug called B12 could help obese mice lose weight and how it works in the body
- Who participated: Mice that were made overweight by eating a high-fat diet, plus laboratory-grown fat cells from mice to understand the mechanism
- Key finding: B12 reduced obesity through two mechanisms: it increased calorie-burning brown fat and decreased storage white fat, outperforming the original berberine compound
- What it means for you: This research suggests B12 could become a new obesity treatment option, though human studies are still needed to confirm safety and effectiveness
The Research Details
Researchers created a new compound called B12 based on berberine, a natural substance found in plants. They tested it on obese mice and compared it to the original berberine. The team measured how much energy the mice burned using special cages that track movement and metabolism. They also examined fat tissue under a microscope to see how it changed. In the laboratory, they grew fat cells and studied how B12 affected their growth and development using genetic testing methods. This multi-level approach—testing in whole animals and isolated cells—helps scientists understand both what B12 does and how it does it.
Testing in both living animals and laboratory cells is important because it shows whether a drug works in a real body and reveals the specific biological pathways involved. This combination approach gives researchers confidence that the results are meaningful and helps explain the mechanism of action, which is crucial for developing safe and effective treatments.
This is original research published in a respected obesity journal. The study used multiple scientific techniques (genetic analysis, protein measurement, cell imaging, and metabolic testing) to confirm findings from different angles. However, the research was conducted only in mice and laboratory cells, not humans, so results may not directly translate to people. The specific sample size of animals tested was not provided in the abstract.
What the Results Show
B12 proved significantly more effective than the original berberine at reducing obesity in mice. The compound worked through two distinct mechanisms. First, it increased the number and activity of brown fat cells—the type of fat that burns calories to produce heat—by activating specific cellular pathways called SIRT1 and AMPK. Second, B12 reduced the amount of white fat (storage fat) by preventing fat cells from developing in the first place. The researchers found that B12 blocked the formation of new fat cells at multiple stages of development, starting with early-stage interference with cell division and continuing through later stages where cells would normally mature into functional fat storage cells.
The study identified specific molecular targets that B12 affects. It reduced expression of proteins called CyclinD1 and C/EBPβ in early fat cell development, and later reduced PPARγ and RXRα, which are master regulators of fat cell maturation. These findings suggest B12 works like a multi-step blocker, stopping fat cell development at several checkpoints rather than just one.
Berberine has been studied for obesity for years, but it has limitations: modest effectiveness and poor absorption by the body. B12 was specifically designed to overcome these problems with better solubility and bioavailability. This research demonstrates that the improved version significantly outperforms the original compound, representing meaningful progress in natural product-based obesity treatment.
This research was conducted entirely in mice and laboratory cell cultures, not in humans. Results in animals don’t always translate to people due to differences in metabolism and physiology. The study doesn’t provide information about potential side effects, optimal dosing, or long-term safety in living organisms. Additionally, the abstract doesn’t specify the exact number of mice used or provide detailed statistical analysis of the results.
The Bottom Line
B12 shows strong promise as an obesity treatment based on this research, but it’s important to note this is early-stage science. Human clinical trials are necessary before B12 can be recommended for people. If future studies confirm these results in humans, B12 could become a valuable treatment option for obesity. Currently, the evidence is strong in laboratory and animal models but not yet applicable to clinical practice.
This research is most relevant to obesity researchers, pharmaceutical companies developing new treatments, and people living with obesity who are interested in emerging therapies. Healthcare providers should follow this research as it advances toward human trials. People currently managing obesity should continue working with their doctors on proven approaches while staying informed about promising new options.
Since this research is in early stages (animal studies only), it will likely take 5-10 years of additional research before B12 could potentially be available as a human treatment. Clinical trials would need to demonstrate safety and effectiveness in people before any medical use.
Frequently Asked Questions
How does B12 help with weight loss differently than regular berberine?
B12 works through two mechanisms: it increases calorie-burning brown fat and blocks white fat cell formation at multiple stages. The original berberine has modest effects and poor absorption, while B12’s improved design makes it significantly more effective at both activating brown fat and preventing new fat storage cells from developing.
Is B12 safe for humans to use right now?
This research was conducted only in mice and laboratory cells, not humans. While results are promising, human clinical trials are necessary to establish safety and effectiveness before B12 can be recommended for people. It’s not yet available as a medical treatment.
When will B12 be available as an obesity treatment?
Since this is early-stage research, B12 likely needs 5-10 years of additional studies including human clinical trials before potential approval. The timeline depends on successful progression through multiple research phases and regulatory review.
What does brown fat do that white fat doesn’t?
Brown fat burns calories to produce heat, increasing energy expenditure and metabolism. White fat stores calories for later use. B12 boosts brown fat activity while reducing white fat accumulation, creating a dual benefit for weight management.
Could B12 work the same way in humans as it did in mice?
While the mechanisms identified in mice are promising, human metabolism differs significantly from mice. Results in animals don’t always translate directly to people. Human clinical trials are essential to determine if B12 produces similar effects and is safe for long-term use in people.
Want to Apply This Research?
- Track daily calorie burn and energy expenditure using activity data, plus weekly measurements of body weight and waist circumference to monitor changes in both brown fat activation and overall fat reduction
- Users could log their daily activity levels and dietary choices while monitoring how their metabolism responds, creating a baseline for comparison if they eventually have access to B12 or similar treatments
- Establish a long-term tracking system that measures metabolic rate (through activity and calorie burn), body composition changes, and weight trends over months to identify patterns and prepare for potential future treatments
This research describes early-stage laboratory and animal studies of a novel compound called B12. These findings have not been tested in humans and should not be interpreted as medical advice or a recommendation for treatment. B12 is not currently approved for human use. Anyone interested in obesity treatment should consult with a healthcare provider about proven, evidence-based options. This article is for educational purposes only and does not replace professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.